Real-World Effectiveness of Upadacitinib in Moderate‑to‑Severe Atopic Dermatitis (AD): Results From Longitudinal Analyses of the CorEvitas AD Registry
Silverberg J, Gooderham M, Bunick C, Calimlim B, Grada A, Muñoz Maldonado Y, Li A, Fergestrom N, Simpson E. Real-World Effectiveness of Upadacitinib in Moderate‑to‑Severe Atopic Dermatitis (AD): Results From Longitudinal Analyses of the CorEvitas AD Registry. SKIN The Journal Of Cutaneous Medicine 2024, 8: s450. DOI: 10.25251/skin.8.supp.450.Peer-Reviewed Original ResearchDermatology Life Quality IndexPP-NRSGlobal Assessment ScaleFollow-up visitAtopic dermatitisQuality of lifeReal-world outcomesSkin clearanceLongitudinal analysisRating ScalePeak Pruritus Numerical Rating ScaleInvestigator Global Assessment scaleSix-month follow-up visitPruritus Numerical Rating ScaleClear/almost clear skinEffect of upadacitinibNon-interventional registryDermatology Life Quality Index scoresNumerical rating scaleAssessment ScaleRegistry of adultsTreating atopic dermatitisEveryday clinical practiceLife Quality IndexImpact of ADEfficacy and Safety of Upadacitinib vs Dupilumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: Week 16 results of an Open-label, Randomized, Efficacy Assessor-Blinded Head-to-Head Phase 3b/4 Study (Level Up)
Silverberg J, Bunick C, Hong H, Mendes-Bastos P, Gold L, Costanzo A, Ibrahim N, Sancho C, Wu X, Han Y, Levy G, Altman K, Calimlim B, Eyerich K. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: Week 16 results of an Open-label, Randomized, Efficacy Assessor-Blinded Head-to-Head Phase 3b/4 Study (Level Up). British Journal Of Dermatology 2024, ljae404. PMID: 39438067, DOI: 10.1093/bjd/ljae404.Peer-Reviewed Original ResearchAtopic dermatitisSecondary endpointsDose escalationOpen-labelClinical responseSafety profile of upadacitinibSafety signalsResponse to systemic therapyPruritus Numerical Rating ScaleSafety of upadacitinibEczematous skin lesionsWeeks of treatmentNumerical rating scaleSeverity Index reductionsChronic skin diseasePost hoc analysisPhase 3b/4Systemic therapyItch responseSystemic treatmentPrimary endpointEczema AreaDupilumabSafety profileSuperior efficacy734 - Efficacy and safety of upadacitinib vs dupliumab in adults and adolescents with moderate-to-severe atopic dermatitis: results of an open-label, efficacy assessor-blinded head-to-head phase 3b/4 study (Level Up)
Silverberg J, Bunick C, Hong H, Mendes-Bastos P, Gold L, Costanzo A, Ibrahim N, Sancho C, Wu X, Han Y, Levy G, Altman K, Eyerich K. 734 - Efficacy and safety of upadacitinib vs dupliumab in adults and adolescents with moderate-to-severe atopic dermatitis: results of an open-label, efficacy assessor-blinded head-to-head phase 3b/4 study (Level Up). British Journal Of Dermatology 2024, 191: ljae266.107. DOI: 10.1093/bjd/ljae266.107.Peer-Reviewed Original ResearchSafety of upadacitinibVenous thromboembolic eventsProportion of patientsAdverse eventsAtopic dermatitisDose escalationSystemic therapyOpen-labelSecondary endpointsAdjudicated major adverse cardiac eventsModerate-to-severe atopic dermatitisResponse to systemic therapyTreatment-emergent adverse eventsWeek 4Major adverse cardiac eventsPruritus Numerical Rating ScaleChronic inflammatory skin diseaseDiscontinuation of study treatmentEczematous skin lesionsOral Janus kinaseSevere adverse eventsAdverse cardiac eventsWeeks of treatmentNumerical rating scaleInflammatory skin diseaseEarly and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2)
Silverberg J, Gooderham M, Paller A, Deleuran M, Bunick C, Gold L, Hijnen D, Calimlim B, Lee W, Teixeira H, Hu X, Zhang S, Yang Y, Grada A, Platt A, Thaçi D. Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2). American Journal Of Clinical Dermatology 2024, 25: 485-496. PMID: 38528257, PMCID: PMC11070400, DOI: 10.1007/s40257-024-00853-4.Peer-Reviewed Original ResearchPatient Global ImpressionModerate-to-severe atopic dermatitisPatients treated with upadacitinibPatient-reported outcomesGlobal ImpressionAtopic dermatitisWeek 1Skin symptomsQuality of lifeTreating moderate-to-severe atopic dermatitisPhase III monotherapy trialsPhase III randomized clinical trialsWeek 8Baseline to week 1Pruritus Numerical Rating ScaleScoring Atopic Dermatitis indexEffect of upadacitinibOral selective Janus kinaseAtopic Dermatitis indexAssessed patient-reported outcomesMinimal clinically important differenceNumerical rating scaleDermatology Life Quality IndexPatient-Oriented Eczema MeasureChronic inflammatory disease